top of page

Thu, Apr 11

|

Zoom link provided following registration

Preventing Recurrence and Improving Outcomes for Your Patients Following Resection of STAGE IIB/C MELANOMA

The Role of Adjuvant Immunotherapy Presented by Jason Luke, MD Associate Director for Clinical Research Director - Immunotherapy and Drug Development Center UPMC Hillman Cancer Center and University of Pittsburgh Pittsburgh, PA

Registration is closed
See other events
Preventing Recurrence and Improving Outcomes for Your Patients Following Resection of STAGE IIB/C MELANOMA
Preventing Recurrence and Improving Outcomes for Your Patients Following Resection of STAGE IIB/C MELANOMA

Time & Location

Apr 11, 2024, 12:00 PM – 1:00 PM

Zoom link provided following registration

Guests

About The Event

Link to Register with MedLearning: https://www.medlearninggroup.com/cme-programming/mel-echo5/

Learning Objectives:

Upon the completion of this program, attendees should be able to:

  • Interpet data from studies evaluating the use of adjuvant immmunotherapy following resection of stage IIB/C Melanoma
  • Facilitate the inclusion of adjuvant immunotherapy following resection of stage IIB/C Melanoma as a part of individualized patient management plans
  • Prepare strategies for detecting and mitigating theirAEs associated with immunotherpaies used for the treatment of patients with early-stage melanoma 
  • Support multidisciplinary team approaches to the management of patients with early-stage melanoma

NURSES: Amedeco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

Share This Event

bottom of page